Earnings Releases·Nov 4, 2026, 4:06 PM ET

Schrödinger — Third Quarter 2026 Earnings Summary

Total revenue increased 19% year-over-year to $64.5 million, driven by a 49% surge in hosted software revenue to $17.2 million and a $11.2 million milestone payment from Structure Therapeutics within drug discovery revenue.
Full-year 2026 guidance was raised for both Annual Contract Value (ACV) to $222–$232 million and drug discovery revenue to $75–$85 million, while operating expenses are projected to remain below 2025 levels.
Operating expenses decreased 13% to $64.4 million, though the net loss widened to $37.7 million from $32.8 million, primarily due to $11.4 million in other expenses related to fair value changes in equity investments.
Strategic developments include a licensing and collaboration agreement with co-founded Tectora Therapeutics, the receipt of FDA Priority Review for the co-invented drug zasocitinib, and the publication of key research in *Nature* and *JACS Au*.